In cancer cells, Runx2 activates cancer-related genes, promotes cells invasive properties [6,8-10], cooperates with oncogenes (e.g., c-myc in T-cell lymphoma development), and suppresses apoptotic and growth arrest pathways [11,12]. This evidence concerns the gene MYC and cancer.